Wahn U, Siraganian R P
J Allergy Clin Immunol. 1980 Jun;65(6):413-21. doi: 10.1016/0091-6749(80)90233-x.
The clinical and immunologic response to immunotherapy with laboratory animal allergens was evaluated. There were 23 patients; 11 had received immunotherapy with 12 different extracts (five mouse, six rat, one rabbit), and 12 were matched untreated patients. As a group, nine of 23 had seasonal hay fever. Among the treated patients nine of 11 subjectively improved with immunotherapy. Blocking antibody titers were determined by serum inhibition of allergen-induced histamine release. Treated patients had mean blocking antibody levels of G30 = 59.3 +/- 38.7. In the untreated patients the antibody level was low (G30 = 4.6 +/- 3.6). The difference between the two groups was highly significant (t test p less than 0.001). The blocking antibody level correlates with both the final weekly allergen dose and also the cumulative allergen dose received during immunotherapy. When pretreatment sera were available a temporal rise in blocking antibody was demonstrated during immunotherapy. In patients allergic to several laboratory animals and treated with one allergen, the blocking antibody response was predominantly specific to the allergen used in immunotherapy. This indicates a lack of cross-reactivity in the IgG response to the major animal allergens. When immunotherapy was discontinued in four patients there was a dramatic decrease in the blocking titer, and after 24 mo the levels were the same as those of untreated patients.
对用实验动物变应原进行免疫治疗的临床和免疫反应进行了评估。共有23例患者；11例接受了用12种不同提取物（5种小鼠、6种大鼠、1种兔）进行的免疫治疗，12例为配对的未治疗患者。作为一个群体，23例中有9例患有季节性枯草热。在接受治疗的患者中，11例中有9例在免疫治疗后主观症状改善。通过血清抑制变应原诱导的组胺释放来测定封闭抗体滴度。接受治疗的患者的平均封闭抗体水平为G30 = 59.3±38.7。在未治疗的患者中，抗体水平较低（G30 = 4.6±3.6）。两组之间的差异具有高度显著性（t检验p＜0.001）。封闭抗体水平与最终每周变应原剂量以及免疫治疗期间接受的累积变应原剂量均相关。当有治疗前血清时，在免疫治疗期间可证明封闭抗体有暂时性升高。在对几种实验动物过敏并接受一种变应原治疗的患者中，封闭抗体反应主要对免疫治疗中使用的变应原具有特异性。这表明对主要动物变应原的IgG反应缺乏交叉反应性。当4例患者停止免疫治疗时，封闭滴度急剧下降，24个月后水平与未治疗患者相同。
